Mirtazapine Add-On Improves Olanzapine Effect on Negative Symptoms of Schizophrenia

被引：2
|
作者：
Caforio, Grazia [1 ]
Di Giorgio, Annabella [2 ]
Rampino, Antonio [1 ]
Rizzo, Miriam [1 ]
Romano, Raffaella [1 ]
Taurisano, Paolo [1 ,2 ]
Fazio, Leonardo [1 ]
De Simeis, Giuseppe [1 ]
Ursini, Gianluca [1 ]
Blasi, Giuseppe [1 ]
Nardini, Marcello [1 ]
Mancini, Michele [3 ]
Bertolino, Alessandro [1 ,2 ]
机构：
[1] Univ Bari, Dept Neurosci & Sense Organs, Grp Psychiat Neurosci, Bari, Italy
[2] IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, FG, Italy
[3] Eli Lilly Italia SpA, Florence, Italy
来源：
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 2013年 / 33卷 / 06期
关键词：
FREELY-MOVING RATS; DOUBLE-BLIND; PREFRONTAL CORTEX; INDUCED INCREASES; FRONTAL-CORTEX; DOPAMINE; NORADRENALINE; RISPERIDONE; CLOZAPINE; RECEPTORS;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：810 / 812
页数：3
相关论文
共 50 条
  • [31] ADD-ON D-SERINE TO ANTI-PSYCHOTICS IN SCHIZOPHRENIA: A RCT FOCUSED ON NEGATIVE SYMPTOMS AND COGNITION
    Weiser, Mark
    Javitt, D. C.
    Heresco-Levy, U.
    Abramovitch, Y.
    Teitlebaum, A.
    Doron, A.
    Levkovitch, Y.
    Davidson, M.
    [J]. SCHIZOPHRENIA BULLETIN, 2009, 35 : 352 - 352
  • [32] Rationale and study design of a trial to assess rTMS add-on value for the amelioration of negative symptoms of schizophrenia (RADOVAN)
    Hebel, T.
    Langguth, B.
    Schecklmann, M.
    Schoisswohl, S.
    Staudinger, S.
    Schiller, A.
    Ustohal, L.
    Sverak, T.
    Horky, M.
    Kasparek, T.
    Skront, T.
    Hyza, M.
    Poeppl, T. B.
    Riester, M. L.
    Schwemmer, L.
    Zimmermann, S.
    Sakreida, K.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2022, 26
  • [33] Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia - A path model investigation
    Stenberg, Jan-Henry
    Terevnikov, Viacheslav
    Joffe, Marina
    Tiihonen, Jari
    Chukhin, Evgeny
    Burkin, Mark
    Joffe, Grigori
    [J]. NEUROPHARMACOLOGY, 2013, 64 : 248 - 253
  • [34] Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia
    Watanabe, Norio
    [J]. EVIDENCE-BASED MENTAL HEALTH, 2011, 14 (01) : 21 - 21
  • [35] Statin add-on therapy for schizophrenia: Is the effect the same for clozapine?
    Kim, David D.
    Barr, Alasdair M.
    Thornton, Allen E.
    Honer, William G.
    Procyshyn, Ric M.
    [J]. PSYCHIATRY RESEARCH, 2018, 263 : 289 - 290
  • [36] Innovative Add-On Treatments for Schizophrenia
    Buckley, Peter F.
    Miller, Brian J.
    [J]. PSYCHIATRIC ANNALS, 2018, 48 (05) : 208 - 209
  • [37] Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia
    Sirota, Pinkhas
    Pannet, Irit
    Koren, Ady
    Tchernichovsky, Eieonora
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2006, 21 (04) : 227 - 234
  • [38] Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of Schizophrenia
    Buchanan, Robert W.
    Panagides, John
    Zhao, Jun
    Phiri, Phillip
    den Hollander, Wil
    Ha, Xianwei
    Kouassi, Alex
    Alphs, Larry
    Schooler, Nina
    Szegedi, Armin
    Cazorla, Pilar
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (01) : 36 - 45
  • [39] Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia
    Kopelowicz, A
    Zarate, R
    Tripodis, K
    Gonzalez, V
    Mintz, J
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (06): : 987 - 993
  • [40] Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study
    Stenberg, Jan-Henry
    Terevnikov, Viatcheslav
    Joffe, Marina
    Tiihonen, Jari
    Tchoukhine, Evgueni
    Burkin, Mark
    Joffe, Grigori
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (04): : 433 - 441
12345